YIH
CRVS icon

Y-Intercept (HK)’s Corvus Pharmaceuticals CRVS Stock Holding History

Y-Intercept (HK)’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$654K Buy
+43,769
New +$607K 0.01% 1224

Other funds holding CRVS

TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
AIM
Avity Investment Management Greenwich, Connecticut $1.57B AUM 35.56% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

Y-Intercept (HK)'s CRVS Position: Q2 2026 in Review

Y-Intercept (HK) opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 43,769 shares worth $654K. The stake represents 0.01% of the portfolio and ranks #1224 among its holdings.

8 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Y-Intercept (HK) held 43,769 shares of Corvus Pharmaceuticals worth $654K as of Q2 2026.
  • Corvus Pharmaceuticals was a new Y-Intercept (HK) position in Q2 2026.
  • Corvus Pharmaceuticals made up 0.01% of Y-Intercept (HK)'s portfolio in Q2 2026, its #1224 holding.
  • 8 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.